id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-6752-0008,FDA,FDA-2017-D-6752,Information Requests and Discipline Review Letters Under GDUFA Guidance for Industry,Other,Guidance,2022-10-12T04:00:00Z,2022,10,2022-10-12T04:00:00Z,,2024-11-07T00:43:07Z,,1,0,09000064853c413c
FDA-2017-D-6752-0006,FDA,FDA-2017-D-6752,"Information Requests and Discipline
Review Letters Under Generic Drug
User Fee Amendments; Guidance for
Industry; Availability",Notice,Notice of Availability,2022-01-27T05:00:00Z,2022,1,2022-01-27T05:00:00Z,,2022-01-27T15:38:05Z,2022-01605,0,0,0900006484f3c6bd
FDA-2017-D-6752-0007,FDA,FDA-2017-D-6752,Information Requests and Discipline Review Letters Under GDUFA Guidance for Industry,Other,Guidance,2022-01-27T05:00:00Z,2022,1,2022-01-27T05:00:00Z,,2024-11-07T00:36:02Z,,1,0,0900006484f3e01a
FDA-2017-D-6752-0002,FDA,FDA-2017-D-6752,"Information Requests and Discipline Review Letters Under GDUFA
Guidance for Industry",Other,Guidance,2017-12-18T05:00:00Z,2017,12,2017-12-18T05:00:00Z,2018-02-17T04:59:59Z,2024-11-07T01:13:01Z,,1,0,0900006482d34589
FDA-2017-D-6752-0001,FDA,FDA-2017-D-6752,Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2017-12-18T05:00:00Z,2017,12,2017-12-18T05:00:00Z,2018-02-17T04:59:59Z,2018-02-17T02:02:50Z,2017-27124,0,0,0900006482d30211